On July 16, 2026, Aditxt, Inc. entered into Amendment No. 2 to its Note Purchase Agreement with Ignite Proteomics LLC and existing investors. The amendment allows a new party to join as an investor, cancels one existing note, and issues two additional notes of equal principal amount. This transaction does not change the aggregate principal amount of the senior secured notes. The notes are secured by substantially all assets of Ignite and the equity held by Aditxt in Ignite. Aditxt, Inc. is a healthcare technology company focused on immune system monitoring and data analytics.

Nasdaq's Hearing Panel denied Aditxt, Inc.'s request to maintain its listing, resulting in the suspension of common stock trading effective at the market open on June 25, 2026. The delisting follows non-compliance with the minimum $1.00 bid price rule and a failure to meet the $2,500,000 minimum stockholders' equity requirement, as the company reported $(35,174,386) in stockholders' equity for the period ended March 31, 2026. The company is ineligible for a compliance period due to previous significant reverse stock splits. Aditxt may request a review by the Nasdaq Listing and Hearing Review Council within 15 days. Aditxt, Inc. is a healthcare technology company.

On June 22, 2026, Aditxt, Inc. entered into an amendment to its June 3, 2026, Note Purchase Agreement with Ignite Proteomics LLC and various investors. This amendment increases the aggregate original principal amount of newly issued senior secured convertible notes to $6,254,355.17. As part of this transaction, the company and its subsidiary, Ignite, issued and sold additional notes with an original principal amount of $769,230.77 for a cash purchase price of $500,000.00. The notes are secured by substantially all assets of Ignite and the equity held by Aditxt in Ignite. Aditxt, Inc. is a healthcare technology company.

On June 10, 2026, Aditxt, Inc. announced that its wholly-owned subsidiary, Ignite Proteomics, LLC, entered into a Business Combination Agreement with Copley Acquisition Corp (a SPAC) and Ignite Proteomics Holdings, Inc. (Pubco). Under the terms, Ignite Proteomics will merge into Pubco, with the aggregate consideration for Ignite's holders valued at $150 million in Pubco common stock, based on a $10.00 per share value. Pubco will also pay Copley Acquisition Sponsors Limited $4 million. Aditxt entered into a Side Letter and Guaranty Agreement to guarantee Ignite's obligations, including the repayment of all Ignite indebtedness. The transaction is subject to SPAC shareholder approval and other customary closing conditions. Aditxt operates in the biotechnology industry, focusing on proteomics and diagnostic solutions.

On June 3, 2026, Aditxt, Inc. and its subsidiary Ignite Proteomics LLC issued senior secured convertible notes with an aggregate original principal amount consisting of approximately $725,000 in cash proceeds plus the consolidation of existing promissory notes totaling $4,444,444.44. The notes include a 35% original issue discount. To secure the notes, Ignite granted a security interest in substantially all its assets, and Aditxt pledged its equity in Ignite. Aditxt operates in the biotechnology industry, focusing on proteomics and diagnostic tools.